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The CRISPR-Cas9 Patent Dispute
BY KATIE THALEN / ON APRIL 26, 2016

The stage has officially been set for one of the largest biotech patent disputes to date. The
stakes are high in this clash between scientific powerhouses: a potential Nobel Prize, the
patent rights to a breakthrough gene-editing process, and (of course) a lot of money for the
research institution involved.
On one side of this battle stands Feng Zhang, a bioengineer and professor from the Broad
Institute of MIT and Harvard. On the other is Jennifer Doudna, a molecular biologist and
professor from the University of California, Berkeley.
The United States Patent and Trademark Office (USPTO) commenced an interference
proceeding to determine which institution will reap the rewards. On January 11, 2016 the
USPTO declared its interference in response to the Suggestion of Interference filed on behalf
of the Regents of the University of California, the University of Vienna, and Emmanuelle
Charpentier (a microbiologist who collaborated with Doudna on the project).
You may be wondering why the parties were able to ask for an interference proceeding postAIA. That is part of what makes this case so complicated. Before President Obama signed
the Leahy-Smith America Invents Act (AIA) in 2011, the U.S. patent system operated on a firstto-invent system. This meant that inventors had to keep diligent records of their work to
prove that they were the first to “reduce the concept to practice.” The AIA took effect on
March 16, 2013, meaning that any application filed after that date would be subject to the
new—much cleaner—“first to file” system. The “first-to-file” system also eliminated the need
for interference proceedings. This case, because of the timing, falls squarely into the inevitable
gray area that comes out of the change in the law.
[1]

There is no contest that Doudna was the first to file for a patent covering the use of CRISPRCas9 to edit genetic code. The problem is that she filed on March 15, 2013– meaning that the
first-to-file system would not apply to her application. Zhang then filed on October 15, 2013
(7 months later). Because of this, the USPTO now has the enormous task of determining who
was truly the first to invent the gene-editing use of CRISPR-Cas9. Because it filed second, the
Broad Institute is named as the “junior party” in the interference proceeding. This means that
they must show that Zhang was actually the first to invent.
Let’s take a step back. CRISPR is an acronym that stands for Clustered Regularly Interspaced
Short Palindromic Repeats. CRISPR refers to the organization of DNA sequences found in the
genomes of microorganisms, but the term has been used to refer to the CRISPR-Cas9 system.
Cas9 is an enzyme produced by the CRISPR system that has the ability to shut a targeted gene
off. In short, we are looking at technology that can edit the DNA sequence. The implications
[2]

of the technology spark a separate–larger–debate about whether and how it may be used to
edit human DNA (read: designer babies). Of course, it may also prove to be life-saving,
allowing doctors to correct the genes of children who would be born with debilitating
disorders. But that line becomes very blurry, very quickly. Keep in mind that one of the two
institutions named above (Broad or Berkeley) will inevitably have the power to license the
technology and set limitations (or, alternatively, refuse to set limitations) on its use. There is
currently no regulatory framework governing CRISPR research or technology, although Zhang
and Doudna have voiced support for a framework governing its use in people. As I said, the
stakes here are high.
[3]

[4]

So, what is the likely outcome?
According to patent attorney and founder of the IPWatchdog Blog Eugene Quinn, the rules
favor the senior party. Here that is Doudna, as she was the first to file the patent. To prevail in
the interference proceeding, the junior party must “come up with proof that they conceived of
an invention and reduced it to practice first.” Evidence in this type of proceeding would
include dated, signed (notarized) lab notebooks. Without this kind of evidence, Quinn says,
Zhang will lose. And if there is a tie, he says, it goes to the senior party.
[5]

[6]

Lawyers on both sides will offer every argument available, and are currently attempting to end
the interference before it even begins by arguing threshold issues. The court has granted
Broad the opportunity to argue that there is nothing to actually dispute since Zhang’s
invention goes beyond Doudna’s. If that threshold argument does not suffice, then Broad will
have to argue (and show) that Zhang actually did invent first. Of course, Broad has many other
backup arguments as well. As for Berkeley, judges have granted them the opportunity to
argue for a reworded count, presumably to include more, to make it a “winner-take-all
fight.” This leaves Berkeley with the crucial decision of how to word the new count.
[7]

The outcome of the threshold issues is impossible to predict; regardless of which side does
eventually prevail, it will probably not be the end of the road for this dispute. The loser will
likely appeal to the U.S. Court of Appeals, and exhaust every legal resource available. Other
parties with similar technology may also assert claims down the road. In sum, keep a lookout
for updates, but don’t hold your breath for a speedy outcome.
Katie Thalen is a second-year law student at the Benjamin N. Cardozo School of Law and a Staff
Editor of the Arts & Entertainment Law Journal. She will be the Executive Editor of Volume 35 of
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